A few years later: Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children

Pepijn Vemer*, Maarten J. Postma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)


This study aimed to calculate the cost-effectiveness of infant pneumococcal vaccination in the Netherlands, using the 13-valent PCV13 vs. the currently used 10-valent PCV10. We adapted a previously published model, using recent estimates of epidemiological and efficacy data. In 12 scenarios, we explored the impact of different assumptions on the incremental cost-effectiveness ratio (ICECER) of PCV13 over PCV10. Taking only direct effects on invasive pneumococcal disease into account, PCV13 was not found to be cost-effective at a price difference of (sic)11 per dose. If herd protection, replacement and non-invasive disease were also taken into account, the ICECER of PCV13 compared with PCV10 was below (sic)30000/QALY gained in 11 of 12 scenarios. PCV13 was considered dominant in the primary scenario with a price difference below (sic)2.63 per dose.

Original languageEnglish
Pages (from-to)1841-1849
Number of pages9
JournalHuman vaccines & immunotherapeutics
Issue number7
Publication statusPublished - Jul-2014


  • Cost-effectiveness
  • Infant vaccination
  • Netherlands
  • PCV
  • Pneumococcal
  • Vaccines
  • child
  • cost effectiveness analysis
  • human
  • infant
  • vaccination

Cite this